Brief: Medigene Q3 EBITDA Loss Narrows To EUR 6.21 Mln

Medigene AG

11/11/2021 07:10

Nov 11 (Reuters) - MEDIGENE AG  MDG1k.DE :
    * FY FORECAST FOR TOTAL REVENUES HAS BEEN INCREASED FROM
PREVIOUSLY EUR7-9 M TO A RANGE OF EUR10-11 M AND FORECAST FOR
RESEARCH AND DEVELOPMENT COSTS HAS BEEN REDUCED FROM PREVIOUSLY
EUR14-20 M TO A RANGE OF EUR11-12 M
    * FY FORECAST FOR EXPECTED EBITDA LOSS HAS IMPROVED TO
EUR7-9 M
(PREVIOUSLY EUR10-17 M)
    * AS OF 30 SEPTEMBER 2021, TOTAL REVENUES HAVE INCREASED BY
EUR622
K TO EUR6,478 K (30 SEPTEMBER 2020: EUR5,856 K), RESEARCH AND
DEVELOPMENT COSTS OF EUR8,806 K ARE EUR7,791 K LOWER THAN IN
PREVIOUS YEAR (30 SEPTEMBER 2020: EUR16,597 K)
    * Q3 EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND
AMORTIZATION (EBITDA) OF EUR-6,208 K ARE EUR10,318 K HIGHER THAN
IN PREVIOUS YEAR (30 SEPTEMBER 2020: EUR-16,526 K)

Further company coverage:  MDG1k.DE 

 (Gdansk Newsroom)
 ((Gdansk.Newsroom@thomsonreuters.com;))